(Albany, United States) As per DelveInsight’s assessment, globally, the Parkinson’s Disease Psychosis Pipeline constitutes 5+ key companies continuously working towards developing 5+ Parkinson’s Disease Psychosis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Parkinson’s Disease Psychosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease psychosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Parkinson’s Disease Psychosis Pipeline treatment landscape of the report, click here @ Parkinson’s Disease Psychosis Pipeline Outlook
Key Takeaways from the Parkinson’s Disease Psychosis Pipeline Report
- DelveInsight’s Parkinson’s Disease Psychosis Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
- The leading companies are working in the Parkinson’s Disease Psychosis market include Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Axovant Sciences Ltd., Anavex Life Sciences Corp., and others.
- Promising Parkinson’s Disease Psychosis Pipeline Therapies in the various stages of development include SEP-363856, Iloperidone, Pimavanserin, aripiprazole, and others.
- On Februray 2023, Annovis Bio Inc announced a study of phase 1 & 2 clinical trials for Posiphen. Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer’s Disease (AD) and Early Parkinson’s Disease (PD).
- On May 2023, Stanford University announced a study of phase 4 clinical trials for Sodium Oxybate. This study is the first clinical trial using sodium oxybate for the treatment of REM sleep behavior disorder (RBD). Sodium oxybate is a drug approved by FDA for the treatment of narcolepsy which has been used “off label” to treat patients with severe RBD. This drug has shown to be effective and well tolerated in patients with RBD (Shneerson, 2009; Liebenthal, 2016; Moghadam, 2017).
Parkinson’s Disease Psychosis Overview
Nonmotor symptoms have an important impact on quality of life in PD patients and their caregivers and are largely recognized as such by a growing number of health care providers. Psychosis is recognized as one of the most frequent and disabling nonmotor symptoms in PD with prevalences of 20% up to 70% in advanced stages of the condition.
For further information, refer to the detailed Parkinson’s Disease Psychosis Unmet Needs, click here for Parkinson’s Disease Psychosis Ongoing Clinical Trial Analysis
Parkinson’s Disease Psychosis Emerging Drugs Profile
- Iloperidone: Vanda Pharmaceuticals
Iloperidone belongs to a class of medications for schizophrenia known as atypical antipsychotics. Acceptance of the NDA application confirms that the application is sufficiently complete for FDA review for the treatment of schizophrenia.
- Ulotaront: Sumitomo Pharma
Ulotaront (SEP-363856) is a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, jointly developed by Sunovion and PsychoGenics Inc, which is a small-molecule oral agent that does not bind to dopamine D2 or serotonin 5-HT2A receptors. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for ulotaront for the treatment of schizophrenia in May 2019.
Parkinson’s Disease Psychosis Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies Parkinson’s disease psychosis. The Parkinson’s Disease Psychosis companies which have their Parkinson’s disease psychosis drug candidates in the most advanced stage, i.e phase II include Vanda Pharmaceuticals.
Request a sample and discover the recent advances in Parkinson’s Disease Psychosis Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Parkinson’s Disease Psychosis Segmentation
Parkinson’s Disease Psychosis Drugs and Companies
- SEP-363856: Sumitomo Pharma America Inc.
- Iloperidone: Vanda Pharmaceuticals
- Pimavanserin: Acadia Pharmaceuticals Inc.
Parkinson’s Disease Psychosis Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Parkinson’s Disease Psychosis Therapeutics Market include-
Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Axovant Sciences Ltd., Anavex Life Sciences Corp., and others.
Dive deep into rich insights for drugs for Parkinson’s Disease Psychosis Pipeline, click here @ Parkinson’s Disease Psychosis Unmet Needs and Analyst Views
Scope of the Parkinson’s Disease Psychosis Pipeline Report
- Coverage- Global
- Companies- Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Axovant Sciences Ltd., Anavex Life Sciences Corp., and others.
- Therapies- SEP-363856, Iloperidone, Pimavanserin, aripiprazole, and others.
- Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Parkinson’s Disease Psychosis Merger and acquisitions, Licensing Activities
Table of Content
- Introduction
- Executive Summary
- Parkinson’s disease psychosis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Parkinson’s disease psychosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Iloperidone: Vanda Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Parkinson’s disease psychosis Key Companies
- Parkinson’s disease psychosis Key Products
- Parkinson’s disease psychosis- Unmet Needs
- Parkinson’s disease psychosis- Market Drivers and Barriers
- Parkinson’s disease psychosis- Future Perspectives and Conclusion
- Parkinson’s disease psychosis Analyst Views
- Parkinson’s disease psychosis Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services